ICON Public (NASDAQ:ICLR) Price Target Cut to $215.00 by Analysts at Citigroup

ICON Public (NASDAQ:ICLR - Get Free Report) had its target price dropped by stock analysts at Citigroup from $290.00 to $215.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a "buy" rating on the medical research company's stock. Citigroup's price objective would indicate a potential upside of 49.26% from the stock's previous close.

A number of other research firms have also recently commented on ICLR. Royal Bank of Canada reiterated an "outperform" rating and set a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. JPMorgan Chase & Co. decreased their target price on ICON Public from $280.00 to $265.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Robert W. Baird dropped their price target on ICON Public from $221.00 to $203.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. William Blair reaffirmed an "outperform" rating on shares of ICON Public in a research report on Tuesday, January 14th. Finally, The Goldman Sachs Group lowered shares of ICON Public from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $250.00 to $200.00 in a research report on Friday, March 21st. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $243.33.

ICON Public Stock Up 1.0 %

Shares of NASDAQ ICLR traded up $1.40 during trading hours on Monday, hitting $144.04. The company had a trading volume of 1,844,325 shares, compared to its average volume of 890,557. ICON Public has a 1-year low of $138.51 and a 1-year high of $347.72. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36. The firm's 50 day moving average is $179.62 and its 200-day moving average is $210.84. The stock has a market capitalization of $11.63 billion, a P/E ratio of 15.11, a price-to-earnings-growth ratio of 1.86 and a beta of 1.24.

ICON Public (NASDAQ:ICLR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating analysts' consensus estimates of $3.41 by $0.01. The firm had revenue of $2.04 billion during the quarter, compared to analysts' expectations of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. On average, analysts expect that ICON Public will post 13.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ICON Public

A number of hedge funds have recently added to or reduced their stakes in ICLR. Sierra Ocean LLC bought a new stake in shares of ICON Public during the 4th quarter valued at $29,000. Park Place Capital Corp lifted its stake in ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company's stock worth $47,000 after purchasing an additional 166 shares during the last quarter. Private Trust Co. NA lifted its position in shares of ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company's stock worth $52,000 after buying an additional 82 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of ICON Public in the 1st quarter valued at approximately $59,000. Finally, GAMMA Investing LLC grew its stake in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock worth $91,000 after buying an additional 169 shares during the last quarter. Institutional investors own 95.61% of the company's stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.